Collegium Pharma reports record Q4/FY2023 revenue; GAAP net income of $31.9M Q4, $48.2M FY

COLLEGIUM PHARMACEUTICAL, INC

2023-FY EPS reported $1.29 revenue$566,767,000

Record Q4 revenue $149.7M (+16% YoY); FY revenue $566.8M (+22% YoY).
GAAP net income $31.9M Q4 ($0.82 diluted) vs loss of $7.2M in Q4 2022; FY net income $48.2M.
Record adjusted EBITDA $104.2M Q4, $367.0M FY (+38% YoY each).
Repurchased $75M shares in 2023; new $150M buyback authorized Jan 2024.
FY 2024 guidance: product revenue $580–595M, adjusted EBITDA $380–395M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COLLEGIUM PHARMACEUTICAL, INC reported the quarterly period and fiscal year ended December 31, 2023 results: revenue $149.7 Million and $566.8 Million, net income $31.9 Million and $48.2 Million, EPS $0.99 GAAP earnings per share (basic) and $0.82 GAAP earnings per share (diluted); $1.43 GAAP earnings per share (basic). Guidance reaffirmed.

Period: the quarterly period and fiscal year ended December 31, 2023
Revenue: $149.7 Million and $566.8 Million
Net income: $31.9 Million and $48.2 Million
EPS: $0.99 GAAP earnings per share (basic) and $0.82 GAAP earnings per share (diluted); $1.43 GAAP earnings per share (basic)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

8-K. --- EX-99.1 (EX-99.1) --- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001558370-24-001524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.